Infections, Nosocomial
4
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
7 treatments under study, led by Doripenem
Research Leaders
7 sponsors active, led by National Institute of Neurological Disorders and Stroke (NINDS)
Related Conditions
Often studied with 8 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
25%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated From Patients With Hospital Acquired Infections in Sohag University Hospitals, Egypt
Management Practices and the Risk of Infection Following Cardiac Surgery
An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Research Network
Common Treatments
- Doripenem1
- Nanoparticle Zinc Oxide1
- Linezolid1
- Molecular Detection Of Antibiotic Resistance1
- Culture Specific Antibiotic Therapy1
Active Sponsors
- National Institute of Neurological Disorders and Stroke (NINDS)1
- Pfizer1
- National Heart, Lung, and Blood Institute (NHLBI)1
- Canadian Institutes of Health Research (CIHR)1
- PriCara, Unit of Ortho-McNeil, Inc.1
Top Investigators
Christiana Care Health Services
Icahn School of Medicine at Mount Sinai
Brigham and Women's Hospital
Related Conditions
- Infection Postoperative Wound1
- Cardiac Surgery1
- Management Practices1
- Bacterial Pneumonia1
- Ventilatorassociated Pneumonia1